Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-09-14

FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

The FDA approved a supplemental application for the irbesartan and hydrochlorothiazide combination from Aurobindo Pharma Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IRBESARTAN AND HYDROCHLOROTHIAZIDE (irbesartan and hydrochlorothiazide)

Snippet

SUPPL AP for IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)